EUVIMEDEUVIMED entdecken
Crossref

Targeting SARS-CoV-2 main protease: a pharmacophore and molecular modeling approach

Nitchakan Darai, Piyatida Pojtanadithee, Kamonpan Sanachai, Thierry Langer, Peter Wolschann, Thanyada Rungrotmongkol

Journal of Molecular Modeling · 2025

DOI: 10.1007/s00894-025-06441-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Modeling, 2025. Verfasst von Nitchakan Darai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok,…. Hauptthemen laut MEDLINE: SARS-CoV-2, Coronavirus 3C Proteases, Antiviral Agents, Protease Inhibitors. Die Arbeit nennt 49 Literaturangaben. Gefördert von: National Research Council of Thailand, Ratchadapisek Somphot Fund, Chulalongkorn University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CONTEXT: The COVID-19 pandemic, driven by SARS-CoV-2, has had a profound impact on global health, with severe respiratory complications being a primary concern. The main protease (Mpro) of SARS-CoV-2 plays a critical role in viral replication, making it an attractive target for therapeutic intervention. This study aimed to identify potential Mpro inhibitors using an integrated computational approach. From an initial pool of 89,200 compounds in the ChemDiv database, a systematic screening process reduced the candidates to 735 through drug-like property predictions and pharmacophore-based virtual screening. Molecular docking against four co-crystal structures of the inhibitor/Mpro complex, followed by molecular dynamics (MD) simulations and binding free energy calculations, identified E912-0363 and G740-1003 as promising candidates with binding affinities comparable to nirmatrelvir. Extended 500-ns MD simulations further established E912-0363 as a highly promising Mpro inhibitor, supporting its potential for therapeutic development as a complementary or alternative treatment to nirmatrelvir. METHODS: Pharmacophore modeling and virtual screening were conducted using the ChemDiv database, reducing 89,200 compounds to 735 candidates based on drug-like property predictions. Molecular docking was performed against four SARS-CoV-2 Mpro co-crystal structures using AutoDock VinaXB and GOLD docking programs. The top five candidates (E912-0363, P635-0261, G740-1003, G069-0804, and 8602-0428) were subjected to 100-ns molecular dynamics (MD) simulations using the AMBER force field. Binding free energy calculations were performed using the MM/GBSA method. Extended 500-ns MD simulations were carried out for the most promising candidate, E912-0363, to evaluate its long-term stability and interaction with the Mpro binding site.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Coronavirus 3C ProteasesAntiviral AgentsProtease InhibitorsCOVID-19 Drug TreatmentMolecular Docking SimulationMolecular Dynamics SimulationHumansCOVID-19Binding SitesProtein BindingPharmacophore

Stichwörter der Autor:innen

Main protease inhibitorsMolecular dockingMolecular dynamics simulationPharmacophore modellingSARS-CoV-2

Substanzen

Coronavirus 3C ProteasesAntiviral AgentsProtease Inhibitors3C-like proteinase, SARS-CoV-2

Autor:innen und Institutionen

  • Center of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, 10330, Thailand.
  • Program in Bioinformatics and Computational Biology, Graduate School, Chulalongkorn University, Bangkok, 10330, Thailand.
  • Department of Biochemistry, Faculty of Science, Khon Kaen University, Khon Kaen, 40002, Thailand.
  • Department of Pharmaceutical Chemistry, Faculty of Chemistry, University of Vienna, 1090, Vienna, Austria.
  • Department of Theoretical Chemistry, University of Vienna, Währinger Strasse 17, 1090, Vienna, Austria. karl.peter.wolschann@univie.ac.at.
  • Center of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, 10330, Thailand. t.rungrotmongkol@gmail.com.

Förderung

  • National Research Council of Thailand
  • Ratchadapisek Somphot Fund, Chulalongkorn University

Zitieren

APA

Darai, N., Pojtanadithee, P., Sanachai, K., Langer, T., Wolschann, P., & Rungrotmongkol, T. (2025). Targeting SARS-CoV-2 main protease: a pharmacophore and molecular modeling approach. Journal of Molecular Modeling. https://doi.org/10.1007/s00894-025-06441-5

Vancouver

Darai N, Pojtanadithee P, Sanachai K, Langer T, Wolschann P, Rungrotmongkol T. Targeting SARS-CoV-2 main protease: a pharmacophore and molecular modeling approach. Journal of Molecular Modeling. 2025. doi:10.1007/s00894-025-06441-5

BibTeX
@article{Darai2025,
  author = {Darai, Nitchakan and Pojtanadithee, Piyatida and Sanachai, Kamonpan and Langer, Thierry and Wolschann, Peter and Rungrotmongkol, Thanyada},
  title = {Targeting SARS-CoV-2 main protease: a pharmacophore and molecular modeling approach},
  journal = {Journal of Molecular Modeling},
  year = {2025},
  doi = {10.1007/s00894-025-06441-5}
}
Kostenlos starten →